BCC 2021 | Cell-free DNA analysis for breast cancer

Maria Panagopoulou, PhD, Democritus University of Thrace, Alexandroupolis, Greece, talks on the identification and validation of clinically valuable predictive or prognostic biomarkers in breast cancer using cell-free DNA (cfDNA) samples. Automated machine learning approaches are used for target discovery. Digital droplet PCR is then used to examine the identified targets in sequential cfDNA clinical samples from patients with breast cancer, allowing the assessment of correlations with clinic-pathological characteristics and treatment responses. This interview took place during the 17th St. Gallen International Breast Cancer Conference.